PMC:7696151 / 18010-18355 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"488","span":{"begin":10,"end":15},"obj":"Gene"},{"id":"495","span":{"begin":84,"end":87},"obj":"Chemical"}],"attributes":[{"id":"A488","pred":"tao:has_database_id","subj":"488","obj":"Gene:3700"},{"id":"A495","pred":"tao:has_database_id","subj":"495","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" with the gp120 glycosylation process, the vaginal implant was projected to release HCQ with the longest possible duration at a concentration greater than 4.34 μg/mL but lower than 21.7 μg/mL. After six days, this implant improved mucosal epithelial integrity, reduced submucosal immune cell recruitment, decreased gene expression and protein of"}